Report
Autolus FIRST LOOK: Uneventful FY23 results, obe-cel's PDUFA in r/r ALL in 4Q24
Autolus reported uneventful FY23 results, with approx. $ 240m in cash (plus $ 600m from the strategic collaboration with BioNTech and public equity raise in February 2024) – enough to fully support the commercialisation of obe-cel in r/r adult ALL, as well as support obe-cel's pipeline expansion towards pivotal data in autoimmunity. Looking ahead, Autolus is set for an eventful year with an FDA decision on obe-cel in r/r adult ALL (PDUFA 16 November), as well as multiple data readouts including initial data from the phase 1 SLE trial by YE24, which we think could position obe-cel to become a pipeline in a product. We reiterate our BUY rating and $11 TP. Autolus is one of our life sciences top picks.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.